Bibliography
- CATLEY MC, SUKKAR MB, CHUNG KF et al.: Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol. Pharmacol. (2006) 70:697-705.
- NAGASHIMA K, SASSEVILLE VG, WEN D et al.: Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood (2006) 107:4266-4273.
- WAELCHLI R, BOLLBUCK B, BRUNS C et al.: Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK. Bioorg. Med. Chem. Lett. (2006) 16:108-112.
- BINGHAM AH, DAVENPORT RJ, GOWERS L et al.: A novel series of potent and selective IKK2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:409-412.
- WEN D, NONG Y, MORGAN JG et al.: A selective small molecule IκB kinase β blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes and mast cells. J. Pharmacol. Exp. Ther. (2006) 317:989-1001.
- SCHOPF L, SAVINAINEN A, ANDERSON K et al.: IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. (2006) 54:3163-3173.
- RAJE N, HIDESHIMA T, ANDERSON KC: Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Rev. Anti-Cancer Ther. (2006) 6:1239-1247.
- KENEALY M, PRINCE HM: Current status of new drugs for the treatment of patients with multiple myeloma. Int. Med. J. (2006) 36:781-789.
- ROWBOTHAM MC: Pharmacologic management of complex regional pain syndrome. Clin. J. Pain (2006) 22:425-429.
- MUNNIKES RJM, MUIS C, BOERSMA M et al.: Intermediate stage complex regional pain syndrome type 1 is unreleated to proinflammatory cytokines. Mediators Inflamm. (2005) 6:366-372.
- HUYGEN FJ, DE BRUIJN AGJ, DE BRUIN MT et al.: Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. (2002) 11:47-51.
- HEIJMANS-ANTONISSEN C, WESSELDIJK F, MUNNIKES RJM et al.: Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. (2006) 1:28398 (Article ID 28398).
- HUYGEN FJPM, RAMDHANI N, VAN TOORENENBERGEN A, KLEIN J, ZIJLSTRA FJ: Mast cells are involved in inflammatory reactions in complex regional pain syndrome type 1. Immunol. Lett. (2004) 91:147-154.
- HUYGEN FJ, NIEHOF S, ZIJLSTRA FJ et al.: Successful treatment of CRPS 1 with anti-TNF. J. Pain Symptom Manage. (2004) 27:101-103.
- CHING DWT, McCLINTOCK A: Successful treatment with low-dose thalidomide in a patient with both Bechet’s disease and complex regional pain syndrome. J. Clin. Rheumatol. (2003) 9:96-98.
- MALAMAS MS, MANAS ES, McDEVITT RE: Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J. Med. Chem. (2004) 47:5021-5040.
- HARRIS HA, ALBERT LM, LEATHURBY Y et al.: Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology (2003) 144:4241-4249.
- HARRIS HA, BRUNER-TAN KL, ZHANG X, OSTEEN KG, LYTTLE CR: A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis. Hum. Reprod. (2005) 20:936-941.
- MILNER JN, HONG MH, NEGRO-VILAR A: New and improved glucocorticoid receptor ligands. Expert Opin. Investig. Drugs (2005) 14(12):1527-1545.
- GLADUE RF, TYLASKA LA, BRISSETTE WH et al.: CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications in inflammatory disease. J. Biol. Chem. (2003) 278:40473-40480.
- HARINGMAN JJ, KRAAN MC, SMEETS TJM, ZWINDERMAN KH, TAK PP: Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:715-721.